Full article: Immunogenicity and safety of an investigational quadrivalent meningococcal conjugate vaccine administered as a booster dose in children vaccinated against meningococcal disease 3 years earlier as toddlers: A Phase III, open-label

Par un écrivain mystérieux
Last updated 26 juillet 2024
Full article: Immunogenicity and safety of an investigational quadrivalent  meningococcal conjugate vaccine administered as a booster dose in children  vaccinated against meningococcal disease 3 years earlier as toddlers: A  Phase III, open-label
Full article: Immunogenicity and safety of an investigational quadrivalent  meningococcal conjugate vaccine administered as a booster dose in children  vaccinated against meningococcal disease 3 years earlier as toddlers: A  Phase III, open-label
Safety, immunogenicity, and immune memory of a novel meningococcal
Full article: Immunogenicity and safety of an investigational quadrivalent  meningococcal conjugate vaccine administered as a booster dose in children  vaccinated against meningococcal disease 3 years earlier as toddlers: A  Phase III, open-label
Immunogenicity and safety of a quadrivalent meningococcal tetanus
Full article: Immunogenicity and safety of an investigational quadrivalent  meningococcal conjugate vaccine administered as a booster dose in children  vaccinated against meningococcal disease 3 years earlier as toddlers: A  Phase III, open-label
Immunogenicity and Safety of a Meningococcal A Conjugate Vaccine
Full article: Immunogenicity and safety of an investigational quadrivalent  meningococcal conjugate vaccine administered as a booster dose in children  vaccinated against meningococcal disease 3 years earlier as toddlers: A  Phase III, open-label
Full article: Immunogenicity and safety of an investigational
Full article: Immunogenicity and safety of an investigational quadrivalent  meningococcal conjugate vaccine administered as a booster dose in children  vaccinated against meningococcal disease 3 years earlier as toddlers: A  Phase III, open-label
Long-term antibody persistence after a booster dose of
Full article: Immunogenicity and safety of an investigational quadrivalent  meningococcal conjugate vaccine administered as a booster dose in children  vaccinated against meningococcal disease 3 years earlier as toddlers: A  Phase III, open-label
Meningococcal serogroups A, C, W-135, and Y tetanus toxoid
Full article: Immunogenicity and safety of an investigational quadrivalent  meningococcal conjugate vaccine administered as a booster dose in children  vaccinated against meningococcal disease 3 years earlier as toddlers: A  Phase III, open-label
Full article: Immunogenicity and safety of an investigational
Full article: Immunogenicity and safety of an investigational quadrivalent  meningococcal conjugate vaccine administered as a booster dose in children  vaccinated against meningococcal disease 3 years earlier as toddlers: A  Phase III, open-label
Available meningococcal vaccines.
Full article: Immunogenicity and safety of an investigational quadrivalent  meningococcal conjugate vaccine administered as a booster dose in children  vaccinated against meningococcal disease 3 years earlier as toddlers: A  Phase III, open-label
Immunogenicity and safety of a quadrivalent meningococcal tetanus
Full article: Immunogenicity and safety of an investigational quadrivalent  meningococcal conjugate vaccine administered as a booster dose in children  vaccinated against meningococcal disease 3 years earlier as toddlers: A  Phase III, open-label
Structured Benefit-Risk Assessment of a New Quadrivalent
Full article: Immunogenicity and safety of an investigational quadrivalent  meningococcal conjugate vaccine administered as a booster dose in children  vaccinated against meningococcal disease 3 years earlier as toddlers: A  Phase III, open-label
Meningococcal Meningitis disease: Malacards - Research Articles
Full article: Immunogenicity and safety of an investigational quadrivalent  meningococcal conjugate vaccine administered as a booster dose in children  vaccinated against meningococcal disease 3 years earlier as toddlers: A  Phase III, open-label
Quadrivalent meningococcal tetanus toxoid-conjugate booster
Full article: Immunogenicity and safety of an investigational quadrivalent  meningococcal conjugate vaccine administered as a booster dose in children  vaccinated against meningococcal disease 3 years earlier as toddlers: A  Phase III, open-label
Recommended Meningococcal Vaccines by Age Group
Full article: Immunogenicity and safety of an investigational quadrivalent  meningococcal conjugate vaccine administered as a booster dose in children  vaccinated against meningococcal disease 3 years earlier as toddlers: A  Phase III, open-label
Emerging Topics in Vaccine Therapeutics for Adolescents and Adults
Full article: Immunogenicity and safety of an investigational quadrivalent  meningococcal conjugate vaccine administered as a booster dose in children  vaccinated against meningococcal disease 3 years earlier as toddlers: A  Phase III, open-label
Full article: Immunogenicity and safety of an investigational

© 2014-2024 escolcontabil.com.br. Inc. ou ses affiliés.